Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ANTH 2.67 -0.34 (-11.30%)
price chart
Anthera Pharmaceuticals: Buy Low Opportunity On Potential Drug Approval
Anthera's lupus drug, Blisibimod, is in stage 3 clinical trial with results expected in the second half of 2016. ... Anthera Pharmaceuticals (NASDAQ:ANTH) is a tiny biotech that trades primarily on hope at this point. The company's stock price moved ...
Franklin Resources Inc Just Opened Huge Anthera Pharmaceuticals Inc Position
Franklin Resources Inc filed with the SEC SC 13G/A form for Anthera Pharmaceuticals Inc. The form can be accessed here: 000003877716000312.
How Many Anthera Pharmaceuticals Inc (NASDAQ:ANTH)'s Analysts Are Bullish?
Hot Watch List: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Mosaic Co (NYSE ...  Stock Transcript
Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Shorted Shares Increased By ...
Anthera Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
California State Teachers Retirement System Increases Stake in Anthera ...  Daily Political
What's Propelling Anthera Pharmaceuticals Inc to Decline So Much?  Sonoran Weekly Review
Why Anthera Pharmaceuticals, Inc. Shares Are Soaring Higher
What: Shares in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) jumped by 10% earlier today after the company announced after the bell yesterday that it would present updated data from its phase 2b study evaluating blisibimod as a treatment for lupus at an ...
Zacks: Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Receives Average ...
Anthera Pharmaceuticals logo Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports.
Recent Broker Updates On Anthera Pharmaceuticals, Inc. (ANTH)  Risers & Fallers
Anthera Pharmaceuticals Inc (ANTH) Upgraded to Buy at Zacks Investment Research
Anthera Pharmaceuticals Inc logo Zacks Investment Research upgraded shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) from a hold rating to a buy rating in a research report sent to investors on Monday, MarketBeat.
-$0.28 Earnings Per Share Expected for Anthera Pharmaceuticals Inc (NASDAQ ...  Zolmax
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Stock Target and Ratings Update
Brokerages Expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to Announce ($0.28 ...
Anthera Pharmaceuticals logo Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports.
Anthera Pharmaceuticals Inc (ANTH) Downgraded to "Hold" at Zacks Investment ...
Anthera Pharmaceuticals logo Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday, AnalystRatings.
Active Stocks: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Alcatel Lucent ...  KC Register
-$0.28 EPS Expected for Anthera Pharmaceuticals Inc (NASDAQ:ANTH) This Quarter
Anthera Pharmaceuticals logo Equities analysts expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to report earnings per share of ($0.28) for the current quarter, Zacks Investment Research reports.
Closing Bell Reports: Anthera Pharmaceuticals, Inc. (ANTH), Vanguard ...  California Turkish Times
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President ...
HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer.
Anthera appoints COO, names new CTO  Seeking Alpha